Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment At Major Danish Hospital
A leading Danish cancer hospital has treated its first patient using RapidArc(R) radiotherapy after installing eight advanced radiotherapy treatment machines from Varian Medical Systems (NYSE: VAR) of Palo Alto, California. Herlev Hospital, to the north-west of Copenhagen, delivered the fast and efficient RapidArc treatment to a prostate cancer patient using a Clinac(R) iX linear accelerator.

In Poll, Massachusetts Voters Critical Of Health Reform
"Only 26 percent of likely voters in Massachusetts believe health care reform has been a success and just 21 percent believe reform has made health care more affordable, according to newly released poll results," The State House News Service/Boston Herald reports. "The Rasmussen Reports poll of 500 likely Massachusetts voters, taken in April, also found only 10 percent said the quality of health care is getting better under the reform law rules here." "The poll was taken before talks stirred in Washington about a national health care reform push and before a wave of news in Massachusetts about difficulty affording the coverage expansions authorized under the 2006 reform law" (6/29).
News of the day
New Democrat Coalition Proposes Independent Panel To Oversee Comparative Effectiveness Research
Members of the moderate New Democrat Coalition on Tuesday proposed legislation (HR 2502) that would establish a non-governmental, independent office to oversee research efforts to compare the effectiveness of medical treatments, CQ HealthBeat reports. The bill would create the Health Care Comparative Effectiveness Research Institute, which would use money remaining from the $1.1 billion included in the economic stimulus package for comparative effectiveness research and additional funding from fees on Medicare and private insurers. HCCERI would be overseen by a 21-member board -- appointed by the U.S. Comptroller General -- that would include HHS officials, patients, physicians, private insurers and others (Norman, CQ HealthBeat, 5/19). In contrast, a panel to oversee comparative effectiveness research established by a provision in the stimulus bill would be made up of government health experts (Mundy, "Washington Wire," Wall Street Journal, 5/19). According to CQ HealthBeat, some people have raised concerns that comparative effectiveness research funded by the stimulus bill would result in research that could be used to deny coverage for certain treatments and that cost would factor disproportionately in such decisions. Rep. Kurt Schrader (D-Ore.), who introduced the bill, said HCCERI"s goal would be to ensure that medical decisions remain between physicians and patients and that both doctors and patients have the most understandable information possible to make such decisions. HCCERI also would make public its methods for deciding which research projects to approve, as well as any links the institute has to industry, its research protocols and the names of researchers. HCCERI would accept public comment before creating new research guidelines, and all research would be subject to peer review. In addition, HCCERI in commissioning studies would take steps to account for differences in patients" gender, race, age and ethnicity (CQ HealthBeat, 5/19).Schrader said that the bill "will bring patients, along with health care providers, physicians and industry, to the decision-making process," adding, "By having a seat at the table, the American people will help drive the direction of research based on what is most important to them" ("Washington Wire," Wall Street Journal, 5/19). Rep. Allyson Schwartz (D-Pa.) said that New Democrats seek to lower costs and improve quality of care, so "the most important thing we can do is to incentivize innovation and to provide that information on the best practices and best interventions and get that information out to providers." Industry Reaction
Nutrition

FDA Requests Labeling Change For Leukotriene Modifiers

The U.S. Food and Drug Administration provided further updated safety information on a class of asthma drugs known as leukotriene modifiers. The FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling) regarding neuropsychiatric events (behavior, mood changes) that have been reported in some persons taking montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo and Zyflo CR). Leukotrienes are chemicals the body releases in response to an inflammatory stimulus, such as when a person breathes in an allergen. Montelukast and zafirlukast are leukotriene receptor antagonists that work by blocking leukotrienes. Zileuton is a leukotriene synthesis inhibitor which works by stopping the formation of certain substances that cause swelling, tightening, and mucus production in the airways. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009